Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. took a tumble today and lost -€0.778 (-11.070%).
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 8 € there is a positive potential of 25.31% for Xeris Biopharma Holdings Inc. compared to the current price of 6.38 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -11.070% | -12.524% | -12.596% | 35.426% | 1.093% | 161.639% | 225.548% |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -1.610% | -0.093% | 14.255% | -72.306% | -61.293% | -71.444% | -95.712% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat